key: cord-0747178-2stsnkwm
authors: Hernandez-Romieu, Alfonso C.; Carton, Thomas W.; Saydah, Sharon; Azziz-Baumgartner, Eduardo; Boehmer, Tegan K.; Garret, Nedra Y.; Bailey, L. Charles; Cowell, Lindsay G.; Draper, Christine; Mayer, Kenneth H.; Nagavedu, Kshema; Puro, Jon E.; Rasmussen, Sonja A.; Trick, William E.; Wanga, Valentine; Chevinsky, Jennifer R.; Jackson, Brendan R.; Goodman, Alyson B.; Cope, Jennifer R.; Gundlapalli, Adi V.; Block, Jason P.
title: Prevalence of Select New Symptoms and Conditions Among Persons Aged Younger Than 20 Years and 20 Years or Older at 31 to 150 Days After Testing Positive or Negative for SARS-CoV-2
date: 2022-02-04
journal: JAMA Netw Open
DOI: 10.1001/jamanetworkopen.2021.47053
sha: 93f7b4bb28af16b3b3572e4d7d7383babff284f1
doc_id: 747178
cord_uid: 2stsnkwm

IMPORTANCE: New symptoms and conditions can develop following SARS-CoV-2 infection. Whether they occur more frequently among persons with SARS-CoV-2 infection compared with those without is unclear. OBJECTIVE: To compare the prevalence of new diagnoses of select symptoms and conditions between 31 and 150 days after testing among persons who tested positive vs negative for SARS-CoV-2. DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed aggregated electronic health record data from 40 health care systems, including 338 024 persons younger than 20 years and 1 790 886 persons aged 20 years or older who were tested for SARS-CoV-2 during March to December 2020 and who had medical encounters between 31 and 150 days after testing. MAIN OUTCOMES AND MEASURES: International Statistical Classification of Diseases, Tenth Revision, Clinical Modification codes were used to capture new symptoms and conditions that were recorded 31 to 150 days after a SARS-CoV-2 test but absent in the 18 months to 7 days prior to testing. The prevalence of new symptoms and conditions was compared between persons with positive and negative SARS-CoV-2 tests stratified by age (20 years or older and young than 20 years) and care setting (nonhospitalized, hospitalized, or hospitalized and ventilated). RESULTS: A total of 168 701 persons aged 20 years or older and 26 665 younger than 20 years tested positive for SARS-CoV-2, and 1 622 185 persons aged 20 years or older and 311 359 younger than 20 years tested negative. Shortness of breath was more common among persons with a positive vs negative test result among hospitalized patients (≥20 years: prevalence ratio [PR], 1.89 [99% CI, 1.79-2.01]; <20 years: PR, 1.72 [99% CI, 1.17-2.51]). Shortness of breath was also more common among nonhospitalized patients aged 20 years or older with a positive vs negative test result (PR, 1.09 [99% CI, 1.05-1.13]). Among hospitalized persons aged 20 years or older, the prevalence of new fatigue (PR, 1.35 [99% CI, 1.27-1.44]) and type 2 diabetes (PR, 2.03 [99% CI, 1.87-2.19]) was higher among those with a positive vs a negative test result. Among hospitalized persons younger than 20 years, the prevalence of type 2 diabetes (PR, 2.14 [99% CI, 1.13-4.06]) was higher among those with a positive vs a negative test result; however, the prevalence difference was less than 1%. CONCLUSIONS AND RELEVANCE: In this cohort study, among persons hospitalized after a positive SARS-CoV-2 test result, diagnoses of certain symptoms and conditions were higher than among those with a negative test result. Health care professionals should be aware of symptoms and conditions that may develop after SARS-CoV-2 infection, particularly among those hospitalized after diagnosis.

Other disorders of autonomic nervous system G90.9 Disorder of the autonomic nervous system, unspecified Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures G40.10

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable G40.101

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, with status epilepticus G40.109

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, without status epilepticus G40.11

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable G40.111

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, with status epilepticus G40.119

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status epilepticus G40.2

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures G40.20

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, with status epilepticus G40.209

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status epilepticus G40.21

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable G40.211

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status epilepticus G40.219

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus 

0.86) 1058/18821 (5.62) 16124/322673 (5.00) 1.12 (1.04, 1.22) 118/1136 (10.39) 937/10072 (9.30) 1.12 (0.88, 1.42) Headache 3682/131406 (2.80) 33758/1125058 (3.00) 0.93 (0.89, 0.98) 517/22162 (2.33)

Autonomic Dysfunction 491/142854 (0.34) 5928/1205120 (0.49) 0.7 (0.62, 0.79)

27) 1.72 (1.17, 2.51) ---------Headache 436/24146 (1.81) 4303/251359 (1.71) 1.05 (0.93, 1.20) 19/1267 (1.50) 801/48392 (1.66) 0.91 (0.50, 1.64)

CI = confidence interval * Unadjusted prevalence ratio was calculated as follows: %PCC among SARS-CoV-2 positive/%PCC among SARS-CoV-2 negative with 99% confidence intervals =

}) †n = persons with symptom or conditions diagnosed in 31-150 days after SARS-CoV-2 testing who did not have the condition recorded in the 18 months to 7 days prior to SARS-CoV-2 testing; total = number of persons with medical encounters 31-150 days after SARS-CoV-2 testing minus the number of persons with medical encounters 31-150 days who had the symptom or condition recorded in the 18 months to 7 days prior to SARS-CoV-2 testing. Total denominators are different for each row due to removal of persons with symptoms and conditions in the baseline period